Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 256

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 256
---
 in the United States, the Company shall pay Baxter $200
per year during the term of this Services Agreement; however, the year the Company will receive an FDA approval to market GelrinC in
the United States, the Company must pay the remining $140 balance for that year within 30 days after receiving such approval. The Company
incurred expenses under the Services Agreement of $20 for the six months ended June 30, 2024 and 2023.

| 3. | In July 2008, the Company                                                                                                                 
 entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company     
 agreed to purchase Tisseel VHSD fibrin sealant Kit ( “Tisseel”), from Teva, with Teva being Baxter’s exclusive                            
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of          
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial term
of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for consecutive
1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply Agreement may
be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either party may terminate
the Supply Agreement in the event of an uncured material breach or insolvency.

| 4. | In March 2019, the Company participated in                                                                                              
 the Horizon 2020 Research and Innovation Framework Programme from European Union through the European Commission Executive Agency       
 for Small and Medium-sized Enterprises (the “EASME”) for its participation in research and development activities of                    
 the Company. Pursuant to the participation in the Programme, the EASME will fund R&D expenses up to total approved